<p><strong>CASI Pharmaceuticals, Inc.</strong>（納斯達克代碼：CASI）的股東們看到股價在過去一個月內大幅下跌 43%，並且抹去了之前的正面表現，肯定不會感到高興。這一近期的下跌使得股東們在過去一年中面臨了災難性的 79% 的損失。</p>
<p>由於股價大幅下跌，CASI Pharmaceuticals 目前可能發出非常看漲的信號，其市銷率（&#34;P/S&#34;）為 0.6 倍，因為在美國生物技術行業中，幾乎一半的公司市銷率超過 10 倍，甚至市銷率高達 86 倍的情況也並不少見。然而，市銷率可能較低是有原因的，需要進一步調查以確定其合理性。</p>
<p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<p>查看我們對 CASI Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145"/></p>
<p>納斯達克 CM:CASI 市銷率與行業比較 2025 年 9 月 30 日</p>
<h3>CASI Pharmaceuticals 的表現如何</h3>
<p>CASI Pharmaceuticals 的表現可以更好，因為其收入增長低於最近大多數其他公司。似乎許多人預計這種乏善可陳的收入表現將持續下去，這抑制了市銷率的增長。如果你仍然喜歡這家公司，你會希望收入不會變得更糟，並且能夠在公司不受歡迎時買入一些股票。</p>
<p>想要了解分析師對公司的完整預測嗎？那麼我們 <strong>免費的</strong>CASI Pharmaceuticals 報告將幫助你揭示未來的趨勢。</p>
<h2>CASI Pharmaceuticals 的收入增長趨勢如何？</h2>
<p>為了證明其市銷率的合理性，CASI Pharmaceuticals 需要實現遠低於行業水平的微弱增長。</p>
<p>回顧過去一年，公司收入實現了 37% 的顯著增長。然而，與三年前相比，收入總共下降了 9.6%，這相當令人失望。因此，不幸的是，我們必須承認公司在這段時間內未能有效地增長收入。</p>
<p>展望未來，唯一覆蓋該公司的分析師的預測顯示，收入增長將進入負增長領域，未來三年每年下降 100%。在行業其他公司預計每年增長 128% 的情況下，這並不好。</p>
<p>考慮到這一點，我們發現 CASI Pharmaceuticals 的市銷率與其行業同行密切匹配，這一點頗具吸引力。然而，考慮到收入在下滑，市銷率是否已經觸底並沒有保證。如果公司未能改善其收入增長，市銷率可能會進一步下降。</p>
<h2>CASI Pharmaceuticals 的市銷率對投資者意味着什麼？</h2>
<p>CASI Pharmaceuticals 的股票大幅下跌，其市銷率也隨之下降。雖然市銷率不應成為你是否購買股票的決定性因素，但它是收入預期的一個相當有效的晴雨表。</p>
<p>顯然，CASI Pharmaceuticals 因其收入下滑的預期而維持低市銷率。由於行業內其他公司預測收入增長，CASI Pharmaceuticals 的糟糕前景使其低市銷率得到了合理解釋。在這種情況下，很難看到股價在短期內強勁上漲。</p>
<p>還有其他重要的風險因素需要考慮，我們發現了 <strong>CASI Pharmaceuticals 的 5 個警告信號</strong>（其中 3 個不可忽視！），在投資之前你應該瞭解這些。</p>
<p>如果你對 CASI Pharmaceuticals 的業務實力 <strong>不確定</strong>，為什麼不探索我們互動式的股票列表，尋找一些你可能錯過的基本面穩健的其他公司呢？</p>

CASI制藥

<p>CASI 製藥（NASDAQ:CASI）在過去一個月的股價下跌了 43%，導致股東在過去一年中損失了 79%。該公司的市銷率（P/S）為 0.6 倍，顯著低於行業同行，這表明對收入增長的潛在擔憂。儘管去年收入增長了 37%，但總收入在三年內下降了 9.6%，預測顯示未來三年收入增長將下降 100%。這一疲弱的前景使得低市銷率得以合理化，短期內股價難以恢復</p>

<p><strong>CASI Pharmaceuticals, Inc.</strong> (NASDAQ:CASI) shareholders won't be pleased to see that the share price has had a very rough month, dropping 43% and undoing the prior period's positive performance. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 79% loss during that time.</p>
<div class="lb-trans"><p><strong>CASI Pharmaceuticals, Inc.</strong>（納斯達克代碼：CASI）的股東們看到股價在過去一個月內大幅下跌 43%，並且抹去了之前的正面表現，肯定不會感到高興。這一近期的下跌使得股東們在過去一年中面臨了災難性的 79% 的損失。</p>
</div><p>Since its price has dipped substantially, CASI Pharmaceuticals may be sending very bullish signals at the moment with its price-to-sales (or &#34;P/S&#34;) ratio of 0.6x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 10x and even P/S higher than 86x are not unusual. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>由於股價大幅下跌，CASI Pharmaceuticals 目前可能發出非常看漲的信號，其市銷率（&#34;P/S&#34;）為 0.6 倍，因為在美國生物技術行業中，幾乎一半的公司市銷率超過 10 倍，甚至市銷率高達 86 倍的情況也並不少見。然而，市銷率可能較低是有原因的，需要進一步調查以確定其合理性。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><p>Check out our latest analysis for CASI Pharmaceuticals</p>
<div class="lb-trans"><p>查看我們對 CASI Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145" alt="" original-src="https://images.simplywall.st/asset/chart/354853-ps-multiple-vs-industry-1-dark-2/1759236687145"/></p>
<p>NasdaqCM:CASI Price to Sales Ratio vs Industry September 30th 2025</p>
<div class="lb-trans"><p>納斯達克 CM:CASI 市銷率與行業比較 2025 年 9 月 30 日</p>
</div><h3>How CASI Pharmaceuticals Has Been Performing</h3>
<div class="lb-trans"><h3>CASI Pharmaceuticals 的表現如何</h3>
</div><p>CASI Pharmaceuticals could be doing better as it's been growing revenue less than most other companies lately. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>CASI Pharmaceuticals 的表現可以更好，因為其收入增長低於最近大多數其他公司。似乎許多人預計這種乏善可陳的收入表現將持續下去，這抑制了市銷率的增長。如果你仍然喜歡這家公司，你會希望收入不會變得更糟，並且能夠在公司不受歡迎時買入一些股票。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on CASI Pharmaceuticals will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析師對公司的完整預測嗎？那麼我們 <strong>免費的</strong>CASI Pharmaceuticals 報告將幫助你揭示未來的趨勢。</p>
</div><h2>How Is CASI Pharmaceuticals' Revenue Growth Trending?</h2>
<div class="lb-trans"><h2>CASI Pharmaceuticals 的收入增長趨勢如何？</h2>
</div><p>In order to justify its P/S ratio, CASI Pharmaceuticals would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>為了證明其市銷率的合理性，CASI Pharmaceuticals 需要實現遠低於行業水平的微弱增長。</p>
</div><p>Retrospectively, the last year delivered an exceptional 37% gain to the company's top line. Still, revenue has fallen 9.6% in total from three years ago, which is quite disappointing. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenues over that time.</p>
<div class="lb-trans"><p>回顧過去一年，公司收入實現了 37% 的顯著增長。然而，與三年前相比，收入總共下降了 9.6%，這相當令人失望。因此，不幸的是，我們必須承認公司在這段時間內未能有效地增長收入。</p>
</div><p>Shifting to the future, estimates from the only analyst covering the company suggest revenue growth is heading into negative territory, declining 100% each year over the next three years. That's not great when the rest of the industry is expected to grow by 128% each year.</p>
<div class="lb-trans"><p>展望未來，唯一覆蓋該公司的分析師的預測顯示，收入增長將進入負增長領域，未來三年每年下降 100%。在行業其他公司預計每年增長 128% 的情況下，這並不好。</p>
</div><p>With this in consideration, we find it intriguing that CASI Pharmaceuticals' P/S is closely matching its industry peers. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>考慮到這一點，我們發現 CASI Pharmaceuticals 的市銷率與其行業同行密切匹配，這一點頗具吸引力。然而，考慮到收入在下滑，市銷率是否已經觸底並沒有保證。如果公司未能改善其收入增長，市銷率可能會進一步下降。</p>
</div><h2>What Does CASI Pharmaceuticals' P/S Mean For Investors?</h2>
<div class="lb-trans"><h2>CASI Pharmaceuticals 的市銷率對投資者意味着什麼？</h2>
</div><p>Shares in CASI Pharmaceuticals have plummeted and its P/S has followed suit. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>CASI Pharmaceuticals 的股票大幅下跌，其市銷率也隨之下降。雖然市銷率不應成為你是否購買股票的決定性因素，但它是收入預期的一個相當有效的晴雨表。</p>
</div><p>It's clear to see that CASI Pharmaceuticals maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other companies in the industry are forecasting revenue growth, CASI Pharmaceuticals' poor outlook justifies its low P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>顯然，CASI Pharmaceuticals 因其收入下滑的預期而維持低市銷率。由於行業內其他公司預測收入增長，CASI Pharmaceuticals 的糟糕前景使其低市銷率得到了合理解釋。在這種情況下，很難看到股價在短期內強勁上漲。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>5 warning signs for CASI Pharmaceuticals</strong> (3 can't be ignored!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>還有其他重要的風險因素需要考慮，我們發現了 <strong>CASI Pharmaceuticals 的 5 個警告信號</strong>（其中 3 個不可忽視！），在投資之前你應該瞭解這些。</p>
</div><p>If you're <strong>unsure about the strength of CASI Pharmaceuticals' business</strong>, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.</p>
<div class="lb-trans"><p>如果你對 CASI Pharmaceuticals 的業務實力 <strong>不確定</strong>，為什麼不探索我們互動式的股票列表，尋找一些你可能錯過的基本面穩健的其他公司呢？</p>
</div>

由於 CASI 製藥公司（NASDAQ:CASI）的股價暴跌 43%，其收入幾乎沒有引起市場的興奮